Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive
复制标题
DOI：
10.1590/0004-282x20130121
复制
发表时间：
2013-10-01
影响因子：
1.4
通讯作者：
Satomi, Massaco
中科院分区：
文献类型：
--
作者：
Fragoso, Yara Dadalti;Mendes, Maria Fernanda;Satomi, Massaco
目的：那他珠单抗是治疗多发性硬化（MS）的一种新的有效药物。在使用这种药物期间发生进行性多灶性白质脑病（PML）的风险，需要更好地理解JC病毒（JCV）感染。本研究的目的是评估使用那他珠单抗的巴西患者中JCV-DNA的患病率。方法：采用实时荧光定量聚合酶链反应（PCR）定性检测血清中的JCV。结果：在接受那他珠单抗治疗的168例MS患者中，86例（51.2%）患者可检测到JCV-DNA。讨论内容：巴西的JCV-DNA数据补充了需要接受那他珠单抗治疗的MS患者中JCV患病率的全球评估。
Objective: Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. Method: Qualitative detection of the JCV in the serum was performed with real-time polymerase chain reaction (PCR). Results: In a group of 168 patients with MS who were undergoing treatment with natalizumab,JCV-DNA was detectable in 86 (51.2%) patients. Discussion: Data on JCV-DNA in Brazil add to the worldwide assessment of the prevalence of the JCV in MS patients requiring treatment with natalizumab.